Jason Saiban, LLB
Jason Saiban is a partner at leading City law firm Charles Russell LLP. Jason specialises in commercial contracts and large-scale projects and advises clients in a broad range of sectors from sports to charities. He has particular expertise in areas relevant to Veriton Pharma including healthcare, technology, distribution, licensing, procurement and outsourcing.
Dr. Hannah Aiken
Director and Chief Scientific Officer
Dr Hannah Aiken joined Veriton Pharma in 2013 as a highly skilled pharmaceutical product development expert. After completing her PhD at Kings College London, Hannah joined MedPharm where she gained extensive product development and analytical experience through the development of a variety of dosage forms. Hannah has developed projects at all stages, from proof of concept through to robust commercial products, including products which have subsequently been awarded a Marketing Authorisation. Hannah is listed as an inventor on a number of patents and has published numerous papers. At Veriton Pharma, Hannah was promoted to Head of Product Development and Medical Services in 2017 and then most recently to Director and Chief Scientific Officer in 2018.
Director Group Finance
Bill Wild is a chartered accountant with a broad range of financial and commercial skills gained firstly at TT Electronics plc, the global electronics group, and then at Greenshields JCB, one of the world’s largest construction equipment dealers. Since joining the company in 2008, he has helped develop policies and procedures that ensure sound financial management and control of the company’s business. He was promoted to Head of Finance in October 2011 and then to Group Finance Director in September 2012, a role in which he focuses on providing financial oversight and strategic guidance to support the future growth of the company.
Chief Commercial Officer
Chris Grimes is a commercial manager and has a wealth of experience within the pharmaceutical industry. Chris gained vast experience managing and launching pharmaceutical products within global markets and delivering technology transfer projects on multiple product ranges. Previously Chris has worked for UCB Pharma Ltd within their Commercial Business, becoming Business Unit Manager of the Global Minijet Franchise. Chris now provides commercial oversight and strategic guidance to support the future growth of Veriton Pharma.
Theresa Wallis is a non-executive director on small company boards. Until May 2017 she was non-executive chairman of LiDCO Group plc, an AIM-quoted medical technology company supplying haemodynamic monitoring equipment to hospitals. Theresa’s executive experience includes working for the London Stock Exchange for 13 years, where from 1995 to 2001 she was chief operating officer of AIM, the market for smaller growing companies. In 2001 she moved into technology commercialisation, and worked for ANGLE plc, a venture management and consulting business, for five years.